denne overvågning skal gives i en opdatering af EU risk management plan eller på tidspunktet for den årlige revurdering, hvis det sker først.
b) Prior to launch in any EU Member State, the MAH will set up an immunosurveillance programme and provide antibody testing for anti-ATryn antibodies to physicians.